Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18738887 | Cancer Treatments | June 2024 | November 2025 | Abandon | 18 | 1 | 1 | No | No |
| 18429111 | [3-(4-METHOXYPHENYL)-1,2,4-OXADIAZOL-5-YL]METHANOL AS AN ANTITUMOR AND ANTIMICROBIAL COMPOUND | January 2024 | June 2025 | Abandon | 16 | 2 | 1 | No | No |
| 18538242 | ANTIGEN BINDING PROTEINS SPECIFICALLY BINDING MAGE-A | December 2023 | December 2024 | Allow | 12 | 2 | 1 | Yes | No |
| 18498843 | ENGINEERED SIRPa VARIANTS AND METHODS OF USE THEREOF | October 2023 | December 2024 | Allow | 13 | 4 | 1 | Yes | No |
| 18368138 | [3-(4-METHOXYPHENYL)-1,2,4-OXADIAZOL-5-YL]METHANOL AS AN ANTITUMOR AND ANTIMICROBIAL COMPOUND | September 2023 | October 2024 | Abandon | 13 | 1 | 1 | No | No |
| 18244135 | BISPECIFIC ANTIBODY MOLECULES BINDING TO CD3 AND EGFRvIII | September 2023 | July 2025 | Allow | 22 | 4 | 0 | Yes | No |
| 18341688 | ANTI-TCR ANTIBODY MOLECULES AND USES THEREOF | June 2023 | September 2025 | Allow | 27 | 4 | 1 | Yes | No |
| 18309488 | USES FOR AND ARTICLE OF MANUFACTURE INCLUDING HER2 DIMERIZATION INHIBITOR PERTUZUMAB | April 2023 | October 2024 | Abandon | 18 | 2 | 1 | No | No |
| 18183878 | IMMUNITY ENHANCING AGENT FOR CANCER BY ALLERGIN-1 ANTAGONIST | March 2023 | June 2025 | Abandon | 27 | 0 | 1 | No | No |
| 18177594 | PEPTIDES AND COMBINATION THEREOF FOR USE IN THE IMMUNOTHERAPY AGAINST CANCERS | March 2023 | November 2025 | Abandon | 33 | 1 | 1 | No | No |
| 18176072 | NOVEL DDR1 ANTIBODIES AND USES THEREOF | February 2023 | March 2025 | Allow | 24 | 2 | 1 | Yes | No |
| 18174892 | ENHANCING ANTI-CANCER ACTIVITY OF IMMUNOMODULATORY FC FUSION PROTEINS | February 2023 | May 2025 | Abandon | 27 | 1 | 0 | No | No |
| 18168930 | CLINICAL ASSESSMENT OF M-PROTEIN RESPONSE IN MULTIPLE MYELOMA | February 2023 | March 2025 | Abandon | 25 | 2 | 0 | Yes | No |
| 18163659 | ANTI-MESOTHELIN ANTIGEN-BINDING MOLECULES AND USES THEREOF | February 2023 | September 2023 | Allow | 8 | 1 | 1 | Yes | No |
| 18163015 | CANCER TREATMENTS | February 2023 | October 2024 | Abandon | 20 | 2 | 1 | No | No |
| 18161070 | ANTIBODIES TARGETING THE B-CELL RECEPTOR OF CHRONIC LYMPHOCYTIC LEUKEMIA AND USES THEREOF | January 2023 | January 2024 | Allow | 11 | 2 | 0 | Yes | No |
| 18157597 | THERAPEUTIC, DIAGNOSTIC, AND PROGNOSTIC METHODS FOR CANCER | January 2023 | October 2023 | Abandon | 9 | 0 | 0 | No | No |
| 18153181 | ANTIBODY MOLECULES WHICH BIND CD45 | January 2023 | June 2024 | Abandon | 17 | 0 | 1 | No | No |
| 18002832 | ANTI-NME ANTIBODY AND METHOD OF TREATING CANCER OR CANCER METASTASIS | December 2022 | August 2025 | Abandon | 32 | 4 | 1 | Yes | No |
| 18052264 | METHODS FOR MONITORING AND TREATING CANCER | November 2022 | August 2025 | Abandon | 33 | 3 | 0 | No | No |
| 18049434 | MIC Antibodies and Binding Agents and Methods of Using the Same | October 2022 | February 2024 | Allow | 16 | 2 | 1 | No | No |
| 17946158 | Anti-TIGIT Antibodies | September 2022 | October 2024 | Abandon | 25 | 2 | 1 | No | No |
| 17815367 | Therapeutic Use of Antibodies Against ENPP3 | July 2022 | July 2023 | Allow | 11 | 2 | 1 | Yes | No |
| 17849016 | PEPTIDES AND COMBINATION THEREOF FOR USE IN THE IMMUNOTHERAPY AGAINST CANCERS | June 2022 | January 2023 | Allow | 7 | 1 | 0 | No | No |
| 17807465 | Method of treating solid cancers and/or metastases thereof, medicaments therefore, and a method of predicting the clinical outcome of treating solid cancers and/or metastases thereof | June 2022 | January 2025 | Abandon | 31 | 2 | 0 | Yes | No |
| 17825202 | RECOMBINANT MONOVALENT ANTIBODIES AND METHODS FOR PRODUCTION THEREOF | May 2022 | November 2024 | Abandon | 30 | 0 | 1 | No | No |
| 17743230 | THERAPEUTIC, DIAGNOSTIC, AND PROGNOSTIC METHODS FOR CANCER | May 2022 | April 2023 | Abandon | 11 | 0 | 0 | No | No |
| 17727888 | ANTI-Eva1 PROTEIN ANTIBODY | April 2022 | December 2023 | Abandon | 20 | 1 | 0 | No | No |
| 17722724 | Heterodimeric Bispecific Antibodies | April 2022 | February 2025 | Abandon | 34 | 1 | 1 | No | No |
| 17719194 | Soluble Universal ADCC-Enhancing Synthetic Fusion Gene and Peptide Technology and Its Use Thereof | April 2022 | October 2025 | Abandon | 42 | 4 | 0 | No | No |
| 17656732 | USES FOR AND ARTICLE OF MANUFACTURE INCLUDING HER2 DIMERIZATION INHIBITOR PERTUZUMAB | March 2022 | August 2024 | Abandon | 29 | 0 | 0 | No | No |
| 17704057 | METHOD, ARRAY AND USE THEREOF | March 2022 | January 2024 | Abandon | 22 | 0 | 1 | No | No |
| 17685036 | ANTI-CCR8 MONOCLONAL ANTIBODIES AND USES THEREOF | March 2022 | September 2023 | Allow | 18 | 2 | 1 | Yes | No |
| 17674365 | MATERIALS AND METHODS FOR TARGETING REGULATORY T CELLS FOR ENHANCING IMMUNE SURVEILLANCE | February 2022 | September 2025 | Abandon | 43 | 4 | 1 | Yes | No |
| 17582908 | Multiple-Variable Dosage Regimen for the Treatment of Cancers with High Expression of EGFR | January 2022 | September 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17559965 | BISPECIFIC ANTIBODY AGAINST CD3 AND CD20 IN COMBINATION THERAPY FOR TREATING DIFFUSE LARGE B-CELL LYMPHOMA | December 2021 | October 2025 | Abandon | 46 | 4 | 1 | No | Yes |
| 17554941 | BISPECIFIC ANTIBODIES AGAINST CEACAM5 AND CD47 | December 2021 | April 2023 | Allow | 16 | 2 | 1 | Yes | No |
| 17543628 | MULTI-SPECIFIC BINDING PROTEINS THAT BIND BCMA, NKG2D AND CD16, AND METHODS OF USE | December 2021 | October 2024 | Abandon | 34 | 5 | 1 | Yes | No |
| 17529017 | ANTI-TCR ANTIBODY MOLECULES AND USES THEREOF | November 2021 | June 2023 | Abandon | 19 | 2 | 1 | Yes | No |
| 17527681 | ANTI-CD98hc ANTIBODY | November 2021 | November 2023 | Abandon | 24 | 1 | 0 | No | No |
| 17517869 | TRIFUNCTIONAL ANTIGEN-BINDING MOLECULE | November 2021 | June 2024 | Abandon | 31 | 2 | 0 | No | No |
| 17496051 | RECOMBINANT FUSION PROTEINS TARGETING CD47 AND PD-L1, PREPARATION AND USE THEREOF | October 2021 | January 2023 | Allow | 16 | 2 | 1 | Yes | No |
| 17492299 | POLYPEPTIDE DIRECTED AGAINST PROTEIN TYROSINE PHOSPHATASE 4A PROTEINS, AND COMPOSITIONS AND METHODS FOR USE THEREOF | October 2021 | February 2024 | Abandon | 29 | 1 | 1 | No | No |
| 17474980 | BISPECIFIC ANTIBODY MOLECULES BINDING TO CD3 AND EGFRvIII | September 2021 | October 2022 | Allow | 13 | 2 | 1 | No | No |
| 17460591 | ANTIBODIES BINDING HUMAN AND MONKEY CD3 AND USES THEREOF | August 2021 | August 2024 | Allow | 35 | 4 | 1 | No | No |
| 17412445 | RECOMBINANT BI-FUNCTIONAL FUSION PROTEINS BINDING CD47 AND FC GAMMA RECEPTOR, PREPARATION AND USE THEREOF | August 2021 | July 2023 | Abandon | 22 | 2 | 1 | Yes | Yes |
| 17371954 | Classification and Treatment of Gastric Cancer | July 2021 | October 2023 | Abandon | 27 | 0 | 1 | No | No |
| 17418838 | ANTIBODY FUSION PROTEIN, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | June 2021 | April 2024 | Abandon | 34 | 0 | 1 | No | No |
| 17358902 | PEPTIDES AND COMBINATION THEREOF FOR USE IN THE IMMUNOTHERAPY AGAINST CANCERS | June 2021 | August 2022 | Allow | 14 | 2 | 0 | Yes | No |
| 17356174 | PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LEUKEMIAS AND OTHER CANCERS | June 2021 | August 2023 | Abandon | 26 | 0 | 1 | No | No |
| 17327565 | METHODS FOR ENHANCING PERMEABILITY TO BLOOD-BRAIN BARRIER, AND USES THEREOF | May 2021 | February 2025 | Abandon | 45 | 0 | 1 | No | No |
| 17316152 | ANTI-CD47 ANTIBODIES AND USES THEREOF | May 2021 | October 2023 | Allow | 30 | 1 | 1 | Yes | No |
| 17228653 | BISPECIFIC FAB FUSION PROTEINS COMPRISING A CD3-BINDING FAB FRAGMENT WITH N-TERMINAL FUSION TO A BINDING DOMAIN AND METHODS OF USE | April 2021 | November 2024 | Abandon | 43 | 3 | 1 | No | No |
| 17193804 | ANTI-C-MET ANTIBODY AND USES THEREOF | March 2021 | December 2023 | Abandon | 34 | 1 | 1 | No | No |
| 17271712 | Kinase Activity In Tumors | February 2021 | March 2025 | Abandon | 49 | 1 | 1 | No | No |
| 17271909 | HUMANIZED ANTI-VEGFR2 SINGLE-CHAIN ANTIBODY AND USE THEREOF | February 2021 | December 2024 | Abandon | 46 | 1 | 0 | No | No |
| 17153923 | PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LEUKEMIAS AND OTHER CANCERS | January 2021 | January 2022 | Abandon | 12 | 2 | 0 | Yes | No |
| 17154783 | METHODS OF TREATING CANCER BASED ON IDENTIFYING MUTATIONS IN THE EXTRACELLULAR DOMAIN III OF EPIDERMAL GROWTH FACTOR RECEPTOR GENE | January 2021 | November 2025 | Abandon | 57 | 4 | 1 | Yes | No |
| 17153922 | PEPTIDES AND COMBINATION THEREOF FOR USE IN THE IMMUNOTHERAPY AGAINST CANCERS | January 2021 | January 2022 | Abandon | 11 | 1 | 0 | No | No |
| 17259491 | COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc-ANTIGEN BINDING DOMAIN CONSTRUCTS TARGETED TO CD38 | January 2021 | April 2024 | Abandon | 39 | 0 | 1 | No | No |
| 17041559 | USE OF PROBDNF REGULATOR IN B CELL-RELATED DISEASES | December 2020 | January 2025 | Abandon | 52 | 1 | 1 | No | No |
| 17055103 | CONDITIONALLY ACTIVATED BINDING PROTEIN COMPRISING A STERICALLY OCCLUDED TARGET BINDING DOMAIN | November 2020 | June 2025 | Abandon | 55 | 2 | 1 | No | No |
| 17095377 | DOSING REGIMENS FOR TARGETED TGF-B INHIBITION FOR USE IN TREATING CANCER IN TREATMENT NAÏVE SUBJECTS | November 2020 | December 2023 | Abandon | 37 | 0 | 1 | No | No |
| 17053558 | PROTEINS BINDING NKG2D, CD16 AND P-CADHERIN | November 2020 | January 2024 | Abandon | 38 | 0 | 1 | No | No |
| 17091883 | ACTIVATABLE BISPECIFIC ANTIBODIES | November 2020 | August 2023 | Abandon | 34 | 0 | 1 | No | No |
| 17089103 | METHOD OF USING PACAP AND VIP PEPTIDES FOR DETECTING SHED OR CIRCULATING TUMOR CELLS IN BIOLOGICAL FLUIDS | November 2020 | April 2024 | Abandon | 41 | 2 | 0 | No | No |
| 17052196 | ANTIBODY SPECIFICALLY BINDING TO C-MET, AND USE THEREOF | November 2020 | May 2024 | Allow | 43 | 2 | 1 | Yes | No |
| 17079640 | Lectin Assay For Assessing Glycoforms As An Early Marker In Disease | October 2020 | June 2024 | Abandon | 43 | 2 | 0 | Yes | No |
| 16958625 | CHIMERIC PROMOTER WITH HIGH TRANSCRIPTIONAL ACTIVITY IN T-CELLS | October 2020 | April 2025 | Abandon | 58 | 2 | 1 | No | No |
| 17067691 | PROTEINS MODIFIED WITH (AMINO) MONOSACCHARIDE-BIOTIN ADDUCT | October 2020 | October 2023 | Abandon | 36 | 1 | 1 | No | No |
| 17046560 | SYNERGISTIC DRUG COMBINATIONS PREDICTED FROM GENOMIC FEATURES AND SINGLE-AGENT RESPONSE PROFILES | October 2020 | November 2025 | Abandon | 60 | 3 | 1 | Yes | No |
| 17025729 | PD-L1-BINDING MOLECULES COMPRISING SHIGA TOXIN A SUBUNIT SCAFFOLDS | September 2020 | November 2023 | Allow | 38 | 2 | 1 | Yes | No |
| 16978278 | METHODS AND KITS FOR DIAGNOSING AND/OR TREATING PERIPHERAL NEUROPATHY | September 2020 | November 2024 | Allow | 50 | 2 | 1 | No | No |
| 16996534 | Multispecific Antigens Binding Fragments and Multspecific Antibodies | August 2020 | March 2025 | Allow | 55 | 4 | 0 | Yes | No |
| 16996510 | Multispecific Antigens Binding Fragments and Multspecific Antibodies | August 2020 | November 2023 | Allow | 39 | 2 | 0 | Yes | No |
| 16994950 | USES FOR AND ARTICLE OF MANUFACTURE INCLUDING HER2 DIMERIZATION INHIBITOR PERTUZUMAB | August 2020 | November 2021 | Abandon | 15 | 2 | 1 | No | No |
| 16992966 | USES FOR AND ARTICLE OF MANUFACTURE INCLUDING HER2 DIMERIZATION INHIBITOR PERTUZUMAB | August 2020 | July 2021 | Abandon | 11 | 1 | 1 | No | No |
| 16943779 | ANTIGEN BINDING PROTEINS SPECIFICALLY BINDING MAGE-A | July 2020 | July 2023 | Allow | 36 | 2 | 1 | No | No |
| 16964828 | ANTI-CD47 ANTIBODIES THAT DO NOT CAUSE SIGNIFICANT RED BLOOD CELL AGLLUTINATION | July 2020 | September 2023 | Abandon | 38 | 1 | 1 | No | No |
| 16962180 | BISPECIFIC ANTIBODY THAT BINDS CD3 AND ANOTHER TARGET | July 2020 | June 2023 | Abandon | 35 | 0 | 1 | No | No |
| 16961545 | ANTIBODIES AGAINST TIM3 AND USES THEREOF | July 2020 | June 2024 | Allow | 47 | 2 | 1 | Yes | No |
| 16916217 | PEPTIDES AND COMBINATION THEREOF FOR USE IN THE IMMUNOTHERAPY AGAINST CANCERS | June 2020 | April 2021 | Abandon | 10 | 1 | 0 | No | No |
| 16915797 | PEPTIDES AND COMBINATION THEREOF FOR USE IN THE IMMUNOTHERAPY AGAINST CANCERS | June 2020 | April 2021 | Abandon | 9 | 1 | 0 | Yes | No |
| 16907820 | RECOMBINANT POLYPEPTIDES AND METHODS FOR USE IN THE TREATMENT OF CANCER | June 2020 | March 2022 | Abandon | 21 | 3 | 1 | Yes | No |
| 16905262 | NOVEL RECOMBINANT BI-FUNCTIONAL FUSION PROTEIN TARGETING CD47 AND FCyR, PREPARATION,AND USE THEROF. | June 2020 | January 2024 | Abandon | 43 | 2 | 1 | Yes | No |
| 16904090 | HUMANIZED ANTIBODY MOLECULES TO CD138 AND USES THEREOF | June 2020 | February 2025 | Allow | 56 | 4 | 1 | No | No |
| 16772512 | MELANOMA CHECKPOINT INHIBITOR DETECTION AND TREATMENT | June 2020 | January 2024 | Abandon | 43 | 0 | 1 | No | No |
| 16877878 | CD19 BINDING MOLECULES AND USES THEREOF | May 2020 | January 2024 | Allow | 44 | 2 | 1 | Yes | No |
| 16806658 | ANTI-TIGIT ANTIBODIES | May 2020 | May 2024 | Allow | 50 | 3 | 1 | Yes | No |
| 16872974 | Fc Variants and Methods for their Production | May 2020 | October 2023 | Allow | 41 | 2 | 1 | Yes | No |
| 16759713 | PREDICTING TUMOR SPECIFICITY OF TARGETED THERAPEUTICS USING ATOMIC FORCE MICROSCOPY (AFM) | April 2020 | October 2022 | Abandon | 30 | 0 | 1 | No | No |
| 16754604 | MULTISPECIFIC ANTIBODY COMPRISING CD137 BINDING DOMAIN AND PDL1 BINDING DOMAIN | April 2020 | July 2024 | Allow | 51 | 2 | 1 | No | No |
| 16805351 | PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LEUKEMIAS AND OTHER CANCERS | February 2020 | February 2021 | Abandon | 11 | 1 | 0 | No | No |
| 16799380 | PEPTIDES AND COMBINATION THEREOF FOR USE IN THE IMMUNOTHERAPY AGAINST CANCERS | February 2020 | June 2021 | Abandon | 16 | 2 | 0 | No | No |
| 16796163 | USES FOR AND ARTICLE OF MANUFACTURE INCLUDING HER2 DIMERIZATION INHIBITOR PERTUZUMAB | February 2020 | April 2022 | Abandon | 26 | 3 | 1 | Yes | No |
| 16788442 | USE OF HE4 AND OTHER BIOCHEMICAL MARKERS FOR ASSESSMENT OF OVARIAN CANCERS | February 2020 | November 2023 | Abandon | 45 | 2 | 0 | No | Yes |
| 16786563 | VARIANTS OF CD38 ANTIBODY AND USES THEREOF | February 2020 | December 2024 | Abandon | 58 | 4 | 1 | Yes | Yes |
| 16737745 | ENHANCING ANTI-CANCER ACTIVITY OF IMMUNOMODULATORY FC FUSION PROTEINS | January 2020 | May 2023 | Abandon | 40 | 2 | 0 | No | No |
| 16721254 | BISPECIFIC ANTIBODY MOLECULES BINDING TO CD3 AND TYRP-1 | December 2019 | January 2023 | Allow | 37 | 3 | 1 | No | No |
| 16621314 | CD38 MODULATING ANTIBODY AGENTS | December 2019 | December 2023 | Allow | 48 | 4 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner ALLEN, MICHAEL D.
With a 25.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 12.7% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner ALLEN, MICHAEL D works in Art Unit 1642 and has examined 488 patent applications in our dataset. With an allowance rate of 26.8%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 38 months.
Examiner ALLEN, MICHAEL D's allowance rate of 26.8% places them in the 3% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by ALLEN, MICHAEL D receive 2.66 office actions before reaching final disposition. This places the examiner in the 78% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by ALLEN, MICHAEL D is 38 months. This places the examiner in the 28% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +52.4% benefit to allowance rate for applications examined by ALLEN, MICHAEL D. This interview benefit is in the 94% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 7.9% of applications are subsequently allowed. This success rate is in the 3% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 26.5% of cases where such amendments are filed. This entry rate is in the 37% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 60.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 50% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 58.6% of appeals filed. This is in the 33% percentile among all examiners. Of these withdrawals, 70.6% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.
When applicants file petitions regarding this examiner's actions, 77.9% are granted (fully or in part). This grant rate is in the 83% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.4% of allowed cases (in the 58% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 1.5% of allowed cases (in the 65% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.